Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited. Materials and methods: This was a dual-cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong-Shuai, Yang, Guang-Jian, Cai, Yi, Li, Jun-Ling, Xu, Hai-Yan, Zhang, Tao, Zhou, Li-Qiang, Wang, Yu-Ying, Wang, Jin-Liang, Hu, Xing-Sheng, Yan, Xiang, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234690/
https://www.ncbi.nlm.nih.gov/pubmed/35770100
http://dx.doi.org/10.3389/fphar.2022.919652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234690/
https://www.ncbi.nlm.nih.gov/pubmed/35770100
http://dx.doi.org/10.3389/fphar.2022.919652

Ejemplares similares